COVID-19 Outbreak Management and Vaccination Strategy in The United States of America.

Sara Aicha Amara, Estefany Daniella Díaz, Lakshmi Krishna Menon, Priyanka Singh, Liudmila Rozanova, Antoine Flahault

Abstract readCase Reports

In one paragraph

Article in Epidemiologia (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara Aicha AmaraGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0001-5207-7956

Estefany Daniella DíazGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.

Lakshmi Krishna MenonGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.

Priyanka SinghGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.

Liudmila RozanovaGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-9544-0054

Antoine FlahaultGlobal Health Institute, University of Geneva, 1211 Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Four months after the first case of COVID-19 was reported in the United States, the SARS-CoV-2 virus had spread to more than 90% of all counties. Although the transmission of the virus can be grossly mitigated through non-pharmaceutical interventions and public health measures, risks of future outbreaks, emergence of more infectious variants, and disruptions to socio-economic life will probably remain until effective vaccines are administered to large portions of the global population. An exceptional collaboration between governments and the scientific community has led to the authorization of eight vaccines globally for full use, four of which were funded and developed in the United States. In this paper, we contextualize epidemiological, political, and economic impacts of the COVID-19 vaccination strategy in the United States of America between 20 January 2020, to 5 May 2021, with a key focus on vaccine hesitancy and public-private partnerships.

Indexed as

COVID-19economic impactepidemiologyglobal healthnon-pharmaceutical interventionspublic healthSARS-CoV-2United Statesvaccinevaccine hesitancyvaccine productionvaccine purchasevaccine rollout

Identifiers

PMID36417235

DOI10.3390/epidemiologia2030031

PMCPMC9620927

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.